

Early psoriatic arthritis: when is the right time to start advanced therapy?

Or Hen , Stephanie R. Harrison, Gabriele De Marco  and Helena Marzo-Ortega 

Ther Adv Musculoskelet Dis

2024, Vol. 16: 1–12

DOI: 10.1177/
1759720X241266727

© The Author(s), 2024.
Article reuse guidelines:
sagepub.com/journals-
permissions

Abstract: Despite significant advances in the treatment of psoriatic arthritis (PsA) in the last two decades, remission remains elusive and there is no cure. Evidence from rheumatoid arthritis (RA) confirming enhanced response and outcome from earlier treatment intervention suggests the plausibility of the window of opportunity in the pathogenesis of RA. Yet, data are lacking in PsA. Although treatment response may be enhanced in shorter disease duration, it is unknown how this early intervention may impact long-term outcomes. Furthermore, it remains to be demonstrated whether there is a best treatment strategy and time of intervention. Crucially, the main hurdle when aiming for early treatment intervention is the ability to achieve a timely diagnosis that highlights the need to focus research efforts on characterizing the very early disease stages including the transition to PsA in the at-risk psoriasis population.

Keywords: advanced therapy, early psoriatic arthritis, treatment strategy

Received: 2 February 2024; revised manuscript accepted: 20 June 2024.

Introduction

Psoriasis (PsO) is a common inflammatory condition that most notably affects the skin but may present with other organ involvement, with an estimated world prevalence that lies between 0.09% and 11.4%.¹ Around 20% of patients suffering from PsO will develop psoriatic arthritis (PsA), with a reported PsA prevalence among PsO patients as high as 34.7%.²

The clinical presentation of PsA is heterogeneous and includes multiple musculoskeletal features, such as peripheral and axial arthritis, enthesitis, nail dystrophy and dactylitis. PsA has been associated with reduced quality of life and increased disability and mortality.³

The complex nature of PsA, its multiple disease phenotypes and the overlapping clinical features with other diseases such as osteoarthritis, make it challenging to diagnose especially early in the disease course. As a result, a diagnostic delay is common,⁴ taking typically double that of rheumatoid arthritis (RA). This is of relevance since even a

6-month delay is associated with limitations of physical functioning and permanent disability despite the wide availability of efficacious drug therapies.^{5,6}

Similar to other chronic conditions including RA, it is expected that a better understanding of the early phases of PsA may lead to an earlier, timely diagnosis opening up a window of opportunity to implement a tailored treatment intervention, that might benefit both joints and skin, minimizing irreversible joint damage or modifying the severity of the disease.

Yet, the lack of useful predictors of progression or biomarkers to allow for the early identification of PsA, especially in the PsO population at risk of developing PsA, is a significant unmet need and a research priority in this disease, as highlighted by researchers and patients alike.⁷ This narrative review aims to summarize the latest evidence on the treatment of PsA, discussing the implications of early intervention and the need to address the lack of evidence and standardized definitions of what is early PsA.

Correspondence to:
Helena Marzo-Ortega
Leeds Institute of
Rheumatic and
Musculoskeletal Medicine,
Second Floor, Chapel
Allerton Hospital,
Chapeltown Road, Leeds
LS7 4SA, UK
h.marzo-ortega@leeds.ac.uk

Or Hen
NIHR Leeds Biomedical
Research Centre, The
Leeds Teaching Hospitals
NHS Trust, Leeds
Institute of Rheumatic and
Musculoskeletal Medicine,
University of Leeds, Leeds,
UK

Department of Medicine
'C', Sheba Medical Center,
Tel HaShomer, Ramat
Gan, Israel

Stephanie R. Harrison
Gabriele De Marco
NIHR Leeds Biomedical
Research Centre, The
Leeds Teaching Hospitals
NHS Trust, Leeds
Institute of Rheumatic and
Musculoskeletal Medicine,
University of Leeds,
Leeds, UK

Stephanie R. Harrison is
also affiliated to Leeds
Institute of Data Analytics,
University of Leeds, Leeds

Current treatment options in PsA

The development of advanced therapies such as the biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) in the early 2000s revolutionized the treatment of PsA.⁸ The first class developed were the tumour necrosis factor inhibitors (TNFi), with the IMPACT trial in 2005 showing the efficacy of Infliximab, a monoclonal antibody, in patients with previous inadequate response to conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs).⁹ Other TNFi followed including a TNF receptor inhibitor (etanercept),¹⁰ two humanized antibodies (adalimumab and golimumab)^{11,12} and a pegolated antibody (certolizumab).¹³ Importantly, all TNFis demonstrated good efficacy and acceptable overall safety profile including risk of infections such as tuberculosis.

The next generation of bDMARDs was aimed at specific targets within the interleukin (IL)-17/IL-23 pathway. Ustekinumab is a monoclonal antibody that binds to the p40 subunit that is found both in IL-12 and -23 leading ultimately to a reduction of IL-23, IL-17 and TNF levels by downregulating the T-helper (Th)17 response. Ustekinumab showed superior efficacy to TNFi for skin PsO and moderate response in the joints of TNF naïve and TNFi-experienced patients,^{14,15} including axial symptoms, as shown on a post hoc analysis of the PSUMMIT trial data,¹⁶ despite negative data stemming from phase II trials in axial Spondyloarthritis (axSpA).¹⁷ IL-17 blockade showed impressive efficacy in both skin and joint symptoms with two blockers of the IL-17A isotope (Secukinumab, Ixekizumab),^{18,19} including axial disease²⁰ and more recently a dual blocker of IL-17A and F isotopes (Bimekizumab).²¹ Two head-to-head trials have been performed to date with Secukinumab and Ixekizumab utilizing Adalimumab as the comparator arm.^{22,23} Although neither was powered to demonstrate superiority, both studies showed numerically higher response rates for IL-17A blockade versus adalimumab in controlling skin outcomes with comparable efficacy in joint outcomes.

The IL-23 inhibitors Guselkumab,²⁴ Risankizumab²⁵ and Tildrakizumab²⁶ all suppress the IL-23/IL-17 axis by inhibiting the p19 subunit of IL-23. Guselkumab demonstrated good efficacy on skin, joints, entheses and dactylitis²⁴ and is currently undergoing trials in axial PsA.²⁷

The latest generation are the small molecules targeted synthetic (ts)DMARDs including the phosphodiesterase 4 (PDE4) and the Janus kinase (JAK) inhibitors. The PDE4 inhibitor Apremilast downregulates pro-inflammatory cytokines TNF and IL-23. Although the efficacy of Apremilast on the skin, joint, entheses and dactylitis is modest, it is a well-tolerated oral agent with a remarkable safety profile.^{28–30}

The JAK inhibitors target one or more of four intracellular signalling molecules, JAK1, JAK2, JAK3 and TYK2, which downregulates the JAK-STAT signalling pathway by inhibiting phosphorylation of target transcription factors that modulate immune cell function, leading to reduced secretion of pro-inflammatory cytokines IL-23, IL-6 and IL-15. Tofacitinib selectively inhibits JAK1 and JAK3 and was shown to have similar efficacy when compared to TNFi, but there are concerns regarding its safety profile which include serious infections, venous thromboembolism and lymphoma.^{31–33} Other JAK inhibitors entering the market are the JAK1 selective upadacitinib³⁴ and filgotinib³⁵ and the TYK2 inhibitor deucravacitinib.³⁶ Whether or not selectivity for different JAK molecules alters efficacy, toxicity and tolerability of the drugs in PsA and other rheumatic diseases remains to be seen.³⁷

Clearly, pharmacological options for PsA have come a long way, carrying an abundance of potent targeted agents, with a variety of modes of action and acceptable safety profiles.

However, most studies to date have focused on polyarticular disease of several years duration, often with established structural joint damage on conventional radiographic imaging.^{8,10,11} There are several reasons for this. Firstly, historical delays in diagnosis mean patients with shorter disease duration were rarely captured in clinical trials, which often included populations who were previously exposed and had inadequate response to conventional therapies, hence needing other treatment options. Moreover, until very recently clinical guidelines for the use of bDMARDs in PsA were modelled on a step-up approach whereby biologics or tsDMARDs could only be offered after previous exposure and failure to achieve optimal disease control or tolerability to at least two csDMARDs.^{38,39} Yet, real-world

experience suggests that PsA presentation has changed over time with individuals being diagnosed at an earlier disease stage, often presenting with lower joint counts.⁴⁰ This has been reflected in clinical recommendations suggesting consideration of b/tsDMARD therapy after failure of at least one csDMARD in oligoarthritis or insufficient response to non-steroidal anti-inflammatory drugs (NSAIDs) or local glucocorticoid injections in enthesitis.⁴¹ Furthermore, unlike the earlier clinical trials of TNFis, clinical trials of newer bDMARDs are more diverse in sex and race and generally include patients with shorter disease duration, lower swollen and tender joint counts (SJC and TJC) and C-reactive protein (CRP) levels at baseline. This is due, in part, to increasing awareness of the condition and earlier diagnosis, as well as advances in the availability and sensitivity of imaging such as ultrasound and Magnetic Resonance Imaging (MRI) that enable earlier detection of subclinical disease activity. While this is indeed a welcome advance in the care and

management of PsA, it is an important confounder that must be considered when trying to directly compare efficacy from clinical trial data of TNFis versus newer b/tsDMARDs.

When is the right time to start b/tsDMARDs in early PsA

Growing awareness among primary and secondary care physicians, the development of dedicated early inflammatory arthritis⁴² and cross-specialty rheumatology/dermatology clinics⁴³ are some of the reasons contributing to earlier recognition and diagnosis of PsA. This, alongside the proven success of early and more intense management of RA,^{44,45} has spurred several clinical trials and observational studies in PsA over the past 5 years (Table 1) aiming to address the question as to whether early bDMARD use could indeed improve patient outcomes in this disease. This topic is now a priority for many clinical working groups and healthcare commissioners.^{7,46}

Table 1. Summary of interventional clinical trials of PsA of short disease duration published up to 2023.

Authors	Trial	Intervention	Population	Disease duration	Results
Mulder et al. ⁴⁷	COMPLETE-PsA	Arm 1: MTX + LEF Arm 2: MTX + Placebo.	N=78 Diagnosis of psoriatic arthritis.	Mean (SD), months All=1.2 (0.0–4.00).	At week 16: PASDAS: 3.1 (SD 1.4) vs 3.7 (SD 1.30) PASDAS low disease activity: 50% (23/39) Arm 1 vs 34% (13/38) in Arm 2; $p=0.019$ MDA: 59% (23/39) vs 32% (12/38); $p=0.013$.
Mease et al. ⁴⁸	Etanercept and Methotrexate as monotherapy or in combination for PsA: Primary results from a randomized, controlled phase III trial (SEAM-PsA).	Arm 1: Oral MTX 20mg + placebo. Arm 2: S.C Etanercept 50mg + placebo. Arm 3: S.C Etanercept 50mg + oral MTX 20mg.	N=851. Established active disease by CASPAR + SJC/TJC >3. No prior bDMARDs. No prior cDMARDs except for MTX used for skin until 6 months prior to screening.	Mean (SD), years: All=3.23 Arm 1=3.6 (6.8), Arm 2=3.1 (6.0), Arm 3=3.0 (6.0).	At week 24: ACR20: 50.7% vs 60.9%*, 65.0%* ACR70: 13.8% vs 29.2%*, 35.7%* MDA: 22.9% vs 35.9%*, 35.7%*. HAQ-DI as a change from baseline, mean (SEM): at week 24=no significant difference; at week 48=0.08 (0.03) vs -0.04 (0.04)*, -0.01 (0.03)*.

(Continued)

Table 1. (Continued)

Authors	Trial	Intervention	Population	Disease duration	Results
van Mens et al. ⁴⁹	Achieving remission in PsA by early initiation of TNF inhibition: a double-blind, randomized, placebo-controlled trial of golimumab plus methotrexate vs placebo plus methotrexate.	Arm 1: S.C golimumab 50 mg monthly + MTX Arm 2: Placebo + MTX.	N=51. Established active disease by CASPAR + SJC and TJC > 3. No prior use of DMARDs (conventional/biologic). One patient did use cDMARDs (Leflunomide) prior to the study in the golimumab group.	Median, years=0.5.	Arm 1 vs Arm 2: DAS-CRP > 1.6: at 8 weeks: 73% vs 42%, at 22 weeks: 81% vs 42%. ACR20: at 8 weeks: 85% vs 38%, at 22 weeks: 85% vs 58%. ACR70: at 8 weeks: 48% vs 0%, at 22 weeks: 58% vs 13%. MDA: at week 8=58% vs 21%, at week 22=80% vs 29%. DAPSA LDA: at week 8=85% vs 33%, at week 22=92% vs 54%.
Wells et al. ⁵⁰	Apremilast monotherapy in DMARD-naïve PsA: results of the randomized, placebo-controlled (PALACE-4) trial.	Initially (week 1): Arm 1: Placebo Arm 2: Apremilast 20 mg BID Arm 3: Apremilast 30 mg BID. After week 24 (re-randomization): Arm 1: Placebo/Apremilast 20 mg Arm 2: Placebo/Apremilast 30 mg Arm 3: Apremilast 20 mg Arm 4: Apremilast 30 mg.	N=527. Established active disease by CASPAR + SJC/TJC > 3 No prior use of DMARDs (conventional/biologic).	Mean (SD), years: All=3.4 Arm 1=3.4 (5.1) Arm 2=3.2 (4.7) Arm 3=3.6 (5.0).	At week 16: ACR20: 15.9% vs 28.0%*, 30.7%*. ACR50: 4.5% vs 11.4%*, 11.4%*. ACR70: no significant difference. HAQ-DI, mean change from baseline: 0.03 vs -0.17, -0.21. At week 52, no control group: Placebo/Apremilast 20, Apremilast 20, Apremilast 30. ACR20: 59.7%, 56.7%, 53.4%, 58.7%. ACR70: 8.8%, 10.3%, 13.7%, 18.1%. HAQ-DI, mean change from baseline: -0.21, -0.25, -0.32, -0.39. DAS28-CRP: 30.6%, 29.4%, 31.5%, 39.1%.
Carron et al. ⁵¹	CRESPA trial	Arm 1: S.C golimumab 50 mg Arm 2: Placebo.	N=60 pSpA by ASAS criteria + Active pSpA defined by arthritis, enthesitis, dactylitis, PGA with VAS ≥40 mm and PGA of pain ≥40 mm at screening and baseline visit. + pSpA symptoms ≤ 12 weeks prior to screening. No treatment naïve.	Mean (SD), weeks: All=4.8 Arm 1=5.2 (2.8) Arm 2=4.4 (2).	Arm 1 vs Arm 2: Clinical remission (defined as the absence of peripheral arthritis, enthesitis and dactylitis): at week 12=28 (70%)* vs 3 (15%), at week 24=30 (75%)* vs 4 (20%). pSpARC 50%: at week 12=22 (55%)* vs 4 (20%), at week 24=22 (55%)* vs 3 (15%). pSpARC 70%: at week 12=20 (50%)* vs 3 (15%), at week 24=16 (40%) vs 3 (15%). ^a

(Continued)

Table 1. (Continued)

Authors	Trial	Intervention	Population	Disease duration	Results
Coates et al. ⁵²	TICOPA trial	Arm 1: Standard therapy, (treating clinician decision) Arm 2: Intensive treatment, (treatment according to MDA score).	Diagnosed with PsA by a rheumatologist + Recent symptom onset (<24 months) No prior use of any DMARDs for articular disease.	Median (IQR), months: Arm 1=0.9 (0.5–2.1) Arm 2=0.7 (0.4–1.8).	At week 48: ACR20* = 55 (62%) vs 37 (44%), ACR50* = 44 (51%) vs 21 (25%), ACR70* = 33 (38%) vs 15 (17%). ^b
Kirkham et al. ⁵³	PRESTA trial	Etanercept 50 mg QW for both arms Arm 1: PsA < 2 years Arm 2: PsA > 2 years.	Original study: N = 752 Post-hoc: N = 373 PsA was established by a rheumatologist + Active disease with > 2 TJC and SJC Not treatment naïve with previous exposure to MTX and steroids.	Median, years: Arm 1 = 0.5 Arm 2 = 7.7.	At 24 weeks: A statistically significant difference between Arm 1 and Arm 2 was not found in ACR 20, 50, 70, MDA, MDA – 38.9% vs 29.4% (<i>p</i> value of 0.08). Patient-reported outcomes: Joint pain, mean change from baseline = –42.1* vs –34.6.

^a**p* Value compared to baseline visit.

^b*Significant *p* value of χ^2 test

Significance is <0.05.

ASAS, Assessment of SpondyloArthritis international Society; bDMARD, biologic Disease Modifying Anti-Rheumatic Drugs; BID, two times a day; CASPAR, Classification for Psoriatic Arthritis criteria; cDMARD, conventional Disease Modifying Anti-Rheumatic Drugs; COMPLETE-PsA, Comparing MTX monotherapy with MTX plus Leflunomide in PsA; CRESPA, Clinical REmission in peripheral SPondyloArthritis; DAPSA, Disease Activity in Psoriatic Arthritis Score; DAS, disease activity score; HAQ-DI, Health Assessment Questionnaire-Disability Index; LEF, leflunomide; LDA, Low Disease Activity; MTX: methotrexate; PASDAS, Psoriatic Arthritis Disease Activity Score; PGA, Patient Global Assessment of disease activity; PRESTA, Psoriasis Randomized Etanercept Study in Patients with PsA; PsA, psoriatic arthritis; pSpARC, Peripheral SpondyloArthritis Response Criteria; QW, every four weeks; SD, standard deviation; SEM, standard error of the mean; SJC, swollen joint count; TICOPA, Tight Control of inflammation in early PsA; TJC, tender joint count; VAS, visual analogue score.

A post hoc analysis of the Psoriasis Randomized Etanercept Study in Patients with PsA trial was the first designed to investigate the effect of disease duration (≤ 2 vs > 2 years) on the outcome of treatment with etanercept 50 mg once weekly in patients with PsA and moderate to severe skin PsO. Significant improvements were seen in both groups in arthritis scores and patient-reported outcome (PRO) measures with a trend to better outcomes in the shorter disease duration group, although the study might be missing the power to detect small changes.⁵³

The SEAM-PsA study, reported by Mease et al. in 2019,⁴⁸ compared methotrexate and etanercept monotherapy versus combination therapy with both agents in patients with a mean PsA duration of 3 years at trial entry (although there was substantial variation, with a standard deviation of 6 years). Although numerically, combination treatment and etanercept monotherapy performed

better than methotrexate alone leading to higher ACR20, ACR70 and minimal disease activity (MDA) responses at week 24, these differences were not statistically significant. Furthermore, HAQ-DI was unchanged between groups suggesting the efficacy of methotrexate in this population, although it has to be noted that there was no placebo arm in the trial. In a contemporary study, van Mens et al. reported on the efficacy of the combination of golimumab + MTX with MTX monotherapy on a much smaller population (*n* = 51) with a short disease duration of half a year (median).⁴⁹ Here, the combo arm significantly outperformed the methotrexate monotherapy arm for all endpoints at week 8 and week 22 (ACR20, ACR70, MDA and DAPSA LDA). An earlier study by Carron et al. in 2017 also showed excellent responses in undifferentiated Spondyloarthritis including PsA, to golimumab monotherapy with 75% of patients achieving remission at week 24 compared to placebo (15%), with the

main characteristic being the very short symptom duration of just 4.8 weeks (mean) for the overall study population.⁵¹ However, both these studies had relatively short interventional periods (24 weeks), with subsequent follow-up reports showing that remission was not maintained with a step-down approach, converting golimumab to MTX in most patients in both studies.^{54,55}

Interestingly, a study by Wells et al.⁵⁰ in 2018 in early PsA, PALACE-4 (median ~3 years duration) comparing different dosing regimens of Apremilast showed that 52-week response rates were similar between all the different regimens for ACR20/70, HAQ-DI and DA28-CRP.

What is the best treatment strategy in PsA?

An important consideration for clinicians treating PsA, beyond which drug(s) to use and when to treat, is what is the optimal treatment strategy to induce prompt and sustained remission. The TIGHT COntrol of inflammation in early PsA trials sought to address this by randomizing early PsA patients (median 0.6 months duration) to either standard care or targeting aggressively towards MDA.⁵² Although the short-term, primary results of the study pointed towards a treat-to-target (T2T), intensive treatment regime as leading to superior outcomes at 6 months, 5-year follow-up data from the study cohort showed comparable outcomes between both treatment arms, with decreased MTX use in all groups, and similar numbers of patients on the T2T arm more likely to still be on bDMARD.⁵⁶ A recent strategy study reported the combination of Leflunomide plus methotrexate alone showing greater improvements in disease activity according to PASDAS scores at week 16, although the combination appeared to be less well tolerated than methotrexate monotherapy.⁴⁷

Overall, these studies all targeted a newly diagnosed, cs and b/tsDMARD naïve population. Taken together and notwithstanding the heterogeneity of study designs, varied inclusion criteria and disease duration cut-offs, together with differing modes of action of each drug, these data suggest that the enhanced efficacy seen in these studies may not be related to the individual drugs but to their use in early, treatment-naïve PsA populations. However, it should be noted that selection bias can occur in clinical trial populations leading to reduced applicability of findings to real-world clinical settings. Furthermore, the longevity of

response and the possibility of whether or not early treatment might enable long-term remission with the withdrawal of bDMARD therapy remains uncertain, and the current European League Against Rheumatism (EULAR) and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations advise caution with drug tapering/withdrawal even in patients who achieve early and sustained responses.^{41,57}

Besides randomized clinical trials, there are few observational studies reporting on real-world outcomes for the use of advanced therapies in early PsA. One observational study published in 2023 is the APROACH study,⁵⁸ a non-interventional prospective 52-week cohort study exploring the effect of Apremilast in patients with early PsA (disease duration of 1.1 years (0.7–1.8) at enrolment). The primary outcome was PsA disease activity at week 24 as measured by cDAPSA. Authors report cDAPSA response rates of 59.7% at 24 weeks (primary endpoint) with response rates of 42.5% and 69.8% at 16 and 52 weeks, respectively. Improvements in secondary endpoints (reduction in PsO body surface area [BSA], resolution of enthesitis/dactylitis, resolution of nail PsA and improvement in EQ-5D-5L score) were also observed at 24 weeks and maintained/improved at 52 weeks.⁵⁸ It is difficult to compare this directly with PALACE-4 and the original Apremilast trials, however, due to differences in primary and secondary endpoints. However, it is encouraging that response for cDAPSA was maintained and even improved at 52 weeks compared with the 24-week primary endpoint, suggesting longevity of Apremilast in early PsA.

Overall, despite growing research in this area, much remains to be understood about when is the right time to start b/tsDMARDs, and particularly whether drug-free remission can be achieved in early PsA. Likewise, the long-term efficacy, tolerability and longevity of b/tsDMARD response when treatment is started in early disease is not known. The potential ramifications for this are far-reaching given that the average age at disease onset/diagnosis is lower for PsA/axSpA when compared to RA, for example, and so patients are facing longer periods of their lives on these medications than would be the case in the context of other rheumatological diseases. The question of if, how and when to reduce or even withdraw biological treatment in patients achieving sustained remission remains unknown. Furthermore, there

may be no hard or fast rules and it is likely that the answer will vary depending on each patient's preference as well as their individual underlying disease phenotype. Dactylitis, for example, is a poor prognostic factor for disease progression suggesting the need for earlier treatment intervention.⁵⁹ Other factors such as uveitis, inflammatory bowel disease, erosive or rapidly progressive radiographic disease or axial involvement may be deemed higher risk for biologic withdrawal or tapering.⁶⁰ This is of particular relevance since the evidence suggests that it can be difficult to regain response to a b/tsDMARD once treatment is interrupted, for example, for infection, pregnancy or surgery. Furthermore, real-world evidence shows that responses to second-/third-/fourth-line b/tsDMARD agents are consistently reduced compared with first line.⁶¹ Thus, there is a significant need for biomarkers to both identify early PsA and assist with these key treatment decisions as we seek to personalize patient care. Recent advances in genomics and hybrid approaches combining clinical, PROs and genomics/bioinformatics data could enable these in the future; however, for now these technologies are only in use in the research setting.⁶²

How early is early

To date, a standardized definition of early PsA is lacking. Bio-pathological models of established PsA have evolved over the past 25 years and have indirectly led to the theorization of the stages preceding the clinical onset of this condition. In particular, the traditional view of PsA as a disease characterized by auto-immunity targeting synovial tissues underwent substantial reconsideration. This was triggered by advanced imaging data^{63,64} highlighting the occurrence of prominent inflammatory processes located in close proximity, yet outside the synovium, in PsA. These observations provided seminal evidence that the enthesis is likely to be the earliest site of inflammation being primed in the musculoskeletal system. This line of thought led to a theoretical model of PsA pathogenesis, focused on the entheses,^{65,66} later reinforced by experiments in animal models of SpA and human tissues,^{67,68} and ultimately leading to the concept of the synovio-entheseal complex.⁶⁹

Crucially, plenty of evidence – stemming from imaging-based research projects – documented the occurrence of enthesopathic and synovitic findings in people with PsO but with no clinical

symptoms and signs of PsA.⁷⁰ However, no consensus exists on how to define – let alone diagnose – ‘pre-clinical’ PsA in clinical practice. This is a significant area of unmet need as the transition from ‘pre-clinical’ to (early) PsA would mark the genuine onset of the early clinical stage of PsA. There are however many challenges when researching this transition phase including the incomplete understanding of the bio-pathologic processes underpinning the development of PsA and the lack of specificity of available imaging methods when assessing the synovial joints, and surrounding enthesis and soft tissues in PsA, with findings of inflammatory features in synovial joints such as effusion, synovial hypertrophy and power-Doppler signal also reported in healthy individuals (up to 52%) in the absence of joint pain.⁷¹ Furthermore, musculoskeletal symptoms occurring during the pre-clinical stages of PsA development are non-specific.⁷² These limitations can clearly contribute to the diagnostic delay experienced by people who develop PsA.⁴ The lack of longitudinal data exploring the transition from ‘pre-clinical’ PsA to early PsA is currently, the main obstacle to consensus on a definition of early PsA.

To facilitate research in this area, an EULAR task force has proposed that three distinct stages are relevant to the prevention of PsA: (1) people with PsO at higher risk of PsA; (2) subclinical PsA and (3) clinical PsA.⁷³ Risk factors include arthralgia as a short-term predictor and the severity of PsO, nail involvement, family history of PsA and obesity considered to be long-term predictors for the development of PsA.⁷³ An operational definition of ‘sub-clinical’ has also been proposed for use in clinical trials aimed at exploring the transition from PsO to PsA. EULAR defines ‘sub-clinical PsA’ as arthralgia (pain affecting the joints) and/or imaging evidence of synovial/entheseal inflammation, but without clinically detected synovitis, in patients affected by PsO. However, these proposals have to be considered only as a first step, mostly intended to facilitate future research, with more data needed to shape the definitions of both ‘sub-clinical’ or ‘early’ PsA. Reflecting the relevant interest in this field of research, other organizations, like the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network, proposed their consensus terminology for preclinical phases of PsA for use in research studies.⁷⁴

Interestingly, register data point towards a ‘window of opportunity’ of 2 years between onset of

musculoskeletal inflammatory symptoms (typically, articular early morning stiffness) and clinical diagnosis of PsA.⁷⁵ However, current evidence shows that a quarter of patients already have radiographic erosions⁷⁶ at the time of diagnosis, even when presenting with less than 2 years of symptom duration, suggesting that disease is already well established with a limited chance of drug-free remission at diagnosis, prompting the question of ‘how early is early’ when aiming to intervene to induce full remission of arthritis or even prevention. Yet, exciting insights are coming from observational studies in PsO with indirect evidence suggesting the potential for the ‘interception’ of PsA before its clinical development. Indeed, two recent retrospective studies^{77,78} reported a lower risk of PsA development in PsO patients treated with a bDMARD compared with those treated with narrow-band ultraviolet light B phototherapy or those treated with topicals or no treatment, with similar incidence rates found (i.e. 1.2 and 1.6 cases per 100 patients/year, respectively) in both cohorts. Furthermore, IL-23/IL-17 axis drug blockers have excellent efficacy on skin outcomes leading to clearance in up to 50% of cases.⁷⁹ Although overall responses in signs and symptoms of PsA are more modest, a rapid improvement of dactylitis, a marker of disease severity in PsA, has been reported, suggesting the potential for disease modification if used in early disease.⁷⁹ Furthermore, another retrospective study of patients with PsO and joint pain found no evidence of current or previous dactylitis in patients given biologic therapy for their skin PsO.⁸⁰ These observations suggest that biological therapy could potentially change or modulate the course of PsA, contributing to a milder or less severe outcome.⁸¹

Conclusion

Response to treatment in PsA may be enhanced when initiated in the early stages of the disease course; however, data are needed to establish the optimal therapeutic strategies and to allow for treatment personalization. These will improve the understanding of the true impact of early treatment and intervention timings on the long-term disease outcome including the avoidance of structural progression and disability prevention. However, early intervention in PsA will only be achieved through the successful shortening of the time to diagnosis. This together with an increased understanding of the factors leading to symptom onset remains one of the main unmet needs to improve the lives of people with PsA.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Author contributions

Or Hen: Investigation; Project administration; Writing – original draft; Writing – review & editing.

Stephanie R. Harrison: Methodology; Writing – review & editing.

Gabriele De Marco: Project administration; Writing – review & editing.

Helena Marzo-Ortega: Conceptualization; Project administration; Writing – original draft; Writing – review & editing.

Acknowledgements

The authors are supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health.

Funding

The authors received no financial support for the research, authorship and/or publication of this article.

Competing interests

OR: none declared. SRH received speaker fees from Janssen and Novartis. GDM received speaker/consultancy fees from Janssen, Novartis. HM-O received research grants from Janssen, Novartis, Pfizer and UCB and honoraria/speaker fees from AbbVie, Amgen, Celgene, Eli-Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB.

Availability of data and materials

All data reported in this paper are specified through the original study publications.

ORCID iDs

Or Hen  <https://orcid.org/0000-0003-3806-7529>

Gabriele De Marco  <https://orcid.org/0000-0003-2406-161X>

Helena Marzo-Ortega  <https://orcid.org/0000-0002-9683-3407>

References

- Danielsen K, Olsen AO, Wilsgaard T, et al. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. *Br J Dermatol* 2013; 168(6): 1303–1310.
- Pariser D, Schenkel B, Carter C, et al. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. *J Dermatolog Treat* 2016; 27(1): 19–26.
- Veale DJ and Fearon U. The pathogenesis of psoriatic arthritis. *Lancet* 2018; 391(10136): 2273–2284.
- Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis: a population-based study. *J Rheumatol* 2021; 48: 1410–1416.
- Tillett W, Jadon D, Shaddick G, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. *Ann Rheum Dis* 2013; 72(8): 1358–1361.
- Haroon M, Gallagher P and FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. *Ann Rheum Dis* 2015; 74(6): 1045–1050.
- Hailey L, Bundy C, Burstow H, et al. The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. *Rheumatology (Oxford)* 2023; 62(8): 2716–2723.
- Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis* 2012; 71(3): 319–326.
- Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum* 2005; 52(4): 1227–1236.
- Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet* 2000; 356(9227): 385–390.
- Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). *Ann Rheum Dis* 2009; 68(5): 702–709.
- Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum* 2009; 60(4): 976–986.
- Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of Certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). *Ann Rheum Dis* 2014; 73(1): 48–55.
- McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet* 2013; 382(9894): 780–789.
- Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3. *Ann Rheum Dis* 2014; 73(6): 990–999.
- Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). *Ann Rheum Dis* 2016; 75(11): 1984–1988.
- Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. *Arthritis Rheumatol* 2019; 71(2): 258–270.
- McInnes IB, Mease PJ and Kirkham B. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2015; 386(9999): 1137–1146.
- Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. *Ann Rheum Dis* 2017; 76: 79–87.

20. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. *Ann Rheum Dis* 2021; 80(5): 582–590.
21. McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). *Lancet* 2023; 401(10370): 25–37.
22. McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. *Lancet* 2020; 395(10235): 1496–1505.
23. Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. *Ann Rheum Dis* 2020; 79(1): 123–131.
24. McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. *Arthritis Rheumatol* 2022; 74(3): 475–485.
25. Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPSAKE 1 study. *Rheumatology (Oxford)* 2023; 62(6): 2113–2121.
26. Mease PJ, Chohan S, Garcia Fructuoso FJ, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. *Ann Rheum Dis* 2021; 80(9): 1147–1157.
27. Gladman DD, Mease PJ, Bird P, et al. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. *Trials* 2022; 23(1): 743.
28. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with Apremilast, an oral phosphodiesterase 4 inhibitor. *Ann Rheum Dis* 2014; 73(6): 1020–1026.
29. Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of Apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. *J Rheumatol* 2016; 43(9): 1724–1734.
30. Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). *Ann Rheum Dis* 2016; 75(6): 1065–1073.
31. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. *N Engl J Med* 2017; 377(16): 1537–1550.
32. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. *N Engl J Med* 2017; 377(16): 1525–1536.
33. Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. *Ann Rheum Dis* 2020; 79(11): 1400–1413.
34. Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. *Ann Rheum Dis* 2021; 80(3): 312–320.
35. Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. *Lancet* 2018; 392(10162): 2367–2377.
36. Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. *N Engl J Med* 2018; 379(14): 1313–1321.
37. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. *Nat Rev Rheumatol* 2017; 13(4): 234–243.
38. Coates LD, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. *Arthritis Rheumatol* 2016; 68(5): 1060–1071.
39. Coates LC, Tillet W, Chandler D, et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. *Rheumatology (Oxford)* 2013; 52(10): 1754–1757.
40. De Marco G, Zabotti A, Baraliakos X, et al. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. *RMD Open* 2023; 9(2): e003143.

41. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. *Ann Rheum Dis* 2024; 83: 706–719.
42. Nisar MK. Early arthritis clinic is effective for rheumatoid and psoriatic arthritides. *Rheumatol Int* 2019; 39(4): 657–662.
43. Raine T, Gkini MA, Irving PM, et al. Maintaining clinical freedom whilst achieving value in biologics prescribing: an integrated cross-specialty consensus of UK dermatologists, rheumatologists and gastroenterologists. *BioDrugs* 2021; 35(2): 187–199.
44. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med* 2000; 343(22): 1594–1602.
45. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. *Lancet* 2008; 372(9636): 375–382.
46. Winthrop KL, Isaacs JD, Mease PJ, et al. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. *Ann Rheum Dis* 2024; 83: 409–416.
47. Mulder MLM, Vriezেকolk JE, van Hal TW, et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomized trial. *Lancet Rheum* 2022; 4: e252–e261.
48. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. *Arthritis Rheumatol* 2019; 71(7): 1112–1124.
49. van Mens LJJ, de Jong HM, Fluri I, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. *Ann Rheum Dis* 2019; 78(5): 610–616.
50. Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naïve psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. *Rheumatology (Oxford)* 2018; 57(7): 1253–1263.
51. Carron P, Varkas G, Cypers H, et al. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study. *Ann Rheum Dis* 2017; 76(8): 1389–1395.
52. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. *Lancet* 2015; 386(10012): 2489–2498.
53. Kirkham B, de Vlam K, Li W, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. *Clin Exp Rheumatol* 2015; 33: 11–19.
54. de Jong HMY, van Mens LJJ, Nurmohamed MT, et al. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial. *Arthritis Res Ther* 2019; 21(1): 208.
55. Carron P, De Craermer A-S, Renson T, et al. TNFi-induced sustained clinical remission in peripheral spondyloarthritis patients cannot be maintained with a step-down strategy based on methotrexate. *Rheumatology (Oxford)* 2021; 60(10): 4880–4883.
56. Coates LC, Mahmood F, Freeston J, et al. Long-term follow-up of patients in the TIGHT CONTROL of inflammation in early Psoriatic Arthritis (TICOPA) trial. *Rheumatology (Oxford)* 2020; 59(4): 807–810.
57. Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. *Nat Rev Rheumatol* 2022; 18(8): 465–479.
58. Sfrikakis PP, Vassilopoulos D, Katsifis G, et al. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study. *Rheumatol Int* 2023; 43(5): 889–902.
59. Dubash S, Alabas OA, Michelena X, et al. Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naïve early psoriatic arthritis. *Ann Rheum Dis* 2022; 81(4): 490–495.
60. Mekhail C, Chouk M, Prati C, et al. Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. *Expert Rev Clin Pharmacol* 2020; 13(5): 505–519.

61. Glintborg B, Di Giuseppe D, Wallman JK, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. *Ann Rheum Dis* 2023; 82(6): 820–828.
62. Pouw J, Leijten E, Radstake T, et al. Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: a review of literature. *Clin Immunol* 2020; 211: 108318.
63. McGonagle D, Khan MA, Marzo-Ortega H, et al. Enthesitis in spondyloarthropathy. *Curr Opin Rheumatol* 1999; 11(4): 244–250.
64. McGonagle D, Benjamin M, Marzo-Ortega H, et al. Advances in the understanding of enthesal inflammation. *Curr Rheumatol Rep* 2002; 4(6): 500–506.
65. Benjamin M and McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. *J Anat* 2001; 199(Pt 5): 503–526.
66. McGonagle D and Emery P. Classification of inflammatory arthritis. *Lancet* 1999; 353(9153): 671.
67. Watad A, Rowe H, Russell T, et al. Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. *Ann Rheum Dis* 2020; 79(8): 1044–1054.
68. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR- γ t+ CD3+CD4–CD8– enthesal resident T cells. *Nat Med* 2012; 18(7): 1069–1076.
69. McGonagle D, Lories RJU, Tan AL, et al. The concept of a ‘synovio-enthesal complex’ and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. *Arthritis Rheum* 2007; 56(8): 2482–2491.
70. Naredo E, Möller I, de Miguel E, et al. High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case–control study. *Rheumatology (Oxford)* 2011; 50(10): 1838–1848.
71. Padovano I, Costantino F, Breban M, et al. Prevalence of ultrasound synovial inflammatory findings in healthy subjects. *Ann Rheum Dis* 2016; 75(10): 1819–1823.
72. De Marco G, Cattaneo A, Battafarano N, et al. Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. *Arch Dermatol Res* 2012; 304(9): 719–726.
73. Zabotti A, De Marco G, Gossec L, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. *Ann Rheum Dis* 2023; 82(9): 1162–1170.
74. Perez-Chada LM, Haberman RH, Chandran V, et al. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. *Nat Rev Rheumatol* 2021; 17(4): 238–243.
75. Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). *Ann Rheum Dis* 2014; 73(2): 407–413.
76. Hen O, Di Matteo A, Dubash S, et al. High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort. *RMD Open* 2024; 10(2): e003841.
77. Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. *Ann Rheum Dis* 2022; 81: 68–73.
78. Acosta Felquer ML, LoGiudice L, Galimberti MT, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. *Ann Rheum Dis* 2022; 81: 74–79.
79. Kerschbaumer A, Smolen JS, Dougados M, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis* 2020; 79: 778–786.
80. Solmaz D, Ehlebracht A, Karsh J, et al. Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence. *Clin Exp Rheumatol* 2020; 38: 257–261.
81. Aydin SZ and Marzo-Ortega H. The changing face of psoriatic arthritis. *Lancet Rheumatol* 2022; 4(5): e313–e315.